Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTR-161 in Acute Ischemic Stroke
NCT04608838Phase 2Completed
- Sponsor
- Teijin Pharma
- Start
- Jan 2019
- Primary completion
- Feb 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human dental pulp mesenchymal stem cell injection in ischemic stroke (6 cohorts), sponsored by Teijin Pharma. Primary endpoint: Percentage of patients who achieved Excellent outcome (mRS ≤1, NIHSS ≤1, BI ≥95) at Day 91. Started Jan 2019; status: completed.
02
Drugs
human dental pulp mesenchymal stem cell injection
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04608838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608838.